| Gene symbol | S | Synonyms | E2 | Type of gene | protein-coding |
| Chromosome | - | Map location | NC_004718.3 (21492..25259) | dbXrefs | |
| Gene perturbation-related omics dataset | PerturbAtlas | ||||
| Description | spike glycoprotein | ||||
| GTO ID | GTC0559 |
| Trial ID | NCT05028374 |
| Disease | Chronic Lymphocytic Leukemia | Amyloidosis | Multiple Myeloma |
| Altered gene | S |
| Therapeutic/Target gene | Therapeutic gene |
| Therapy | mRNA vaccine |
| Treatment | Moderna COVID-19 Vaccine |
| Location approved | US, Canada, Israel, EU, Switzerland, Singapore, Qatar, Vietnam, UK, Philippines, Thailand, Japan, South Korea, Brunei, Paraguay, China, Botswana, India, Indonesia, Saudi Arabia, Mexico, Australia, Nigeria, Colombia |
| Phase | Phase2 |
| Recruitment status | Completed |
| Title | Phase II Trial Evaluating the Efficacy of Moderna COVID-19 Vaccine Booster Dosing in Patients With Hematologic Malignancies Who Did Not Have an Adequate Response to Prior Vaccination |
| Year | 2021 |
| Country | United States |
| Company sponsor | Barbara Ann Karmanos Cancer Institute |
| Other ID(s) | 2021-036 |
| Vector information | |||
|
|||
| Cohort1: Multiple myeloma and amyloidosis_not develop an anti-spike antibody | |||||||||||||
|
|||||||||||||
| Cohort2: other hematologic malignancies_not develop an anti-spike antibody | |||||||||||||
|
|||||||||||||
| Cohort3: multiple myeloma, amyloidosis, or other hematologic malignancy_weak positive response | |||||||||||||
|
|||||||||||||